SCHEMBL30765726

SCHEMBL30765726

COC(=O)Cn1c(-c2ccc(O[C@@H]3CO[C@H]4[C@@H]3OC[C@H]4OCc3ccccc3)cc2)ncc(N)c1=O

nearest known ligand 0.44

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.44
CMA1 P23946 12/20 0.44
ELANE P08246 6/20 0.43
CTRC Q99895 4/20 0.43
CTSG P08311 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765493 0.92 BCHE (0.44) BCHECMA1ELANECTRC
SCHEMBL30765771 0.88 ELANE (0.44) CMA1ELANECTRC
SCHEMBL30765813 0.83 ELANE (0.42) BCHEELANE
SCHEMBL30765568 0.82 ELANE (0.43) CMA1ELANECTRC
SCHEMBL30765664 0.81 BCHE (0.44) BCHEELANE
SCHEMBL30766052 0.79 KLK7 (0.42) BCHEELANE
SCHEMBL30765638 0.78 GAA (0.41) BCHEELANE
SCHEMBL30765599 0.77 CTRC (0.54) CMA1ELANECTRC
SCHEMBL30765856 0.77 KLK7 (0.40) BCHEELANE
SCHEMBL6804164 0.75 CMA1 (0.48) CMA1ELANECTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed